Chinese innovative biopharmaceutical firm Mabwell BioScience has closed 1.97 billion yuan ($278 million) in a Series A round of financing led by the country’s private equity firm Shenzhen Shiyu Investment Management.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
